Feed AVXL
AV
Anavex Life Sciences Corp. AVXL NASDAQ · Healthcare · United States
$0.99 -6.66% -$0.07
Summary
50 / 100 · Bulios Score
Valuation 100Growth 0Profitability -Quality 0Debt 100Stability 65
What speaks for it
- It has no debt and holds $118.3M in cash.
- It beat profit estimates 7 times in the last 8 quarters.
What to watch
- It passes only 1 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapIs it growing?
It is shrinkingRevenue (USD)
2021202220232024202520262027
Diluted EPS (USD)
2021202220232024202520262027
- Analyst estimate
There is not enough revenue history yet to say how fast it grows.
Growth in detailDoes it make money?
Over the last 12 months it made a loss of $13.0M.
Profitability in detailIs it financially healthy?
YesCash and short-term investments $118.3M
Debt $0.00
Free cash flow over 12 months -$33.7M
It has no debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 11
- Hold 2
- Sell 0
Today's price within the analysts' price targets
Today's price $0.99 Average target $11
$0.99 $11
The average target of $11 is 1,012% above today's price. 85% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.